Speak up: Push back against FDA's reclassification of DTE

FDA’s reclassification of DTE as a biologic is unnecessary, scientifically flawed, and demonstrably harmful to patients. It strips away choice, likely increases prices, and hands control of a critical therapy to a single drugmaker.

FDA’s misguided move to ban compounded desiccated thyroid extract (DTE) threatens to strip patients of access to a therapy they’ve relied on safely for over a century. Thousands of patients will be left without an option that works for them. We must push back against this unnecessary overreach by the FDA so that your patients are not collateral damage in a policy change that effectively clears the field to create a monopoly for one drugmaker. That’s why APC has launched a grassroots push to mobilize prescribers and patients: compounding.com/thyroid

1. Share the campaign with your DTE patients and prescribers.

2. Submit comments to FDA with just a few clicks.